Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies

NCT05213572 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.

NCT NCT05213572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05213572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Phase
Observational
Overall status
Recruiting
Start date
March 24, 2022
Completion date
June 1, 2035
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mortality in sickle cell, sickle cell cardiopulmonary complications, sickle cell life expectancy and risk factors for early death, sickle cell lung disease and sudden death, sickle cell organ damage